If you are headed to BioCentury Inc.’s BioEquity Europe Conference and are interested in learning how ImmunoScape is working toward the development of TCR-based therapies against solid tumors, send us a message. Our Co-founder and VP of Innovation Michael...
Next-gen TCR-based therapies against solid tumors have the power to disrupt and transform the development, delivery, and efficacy for cancer patients. Dan Macleod, ImmunoScape’s SVP of Discovery, will be an expert speaker at this year’s TCR-based Therapies for Solid...
SAN DIEGO & SINGAPORE–(BUSINESS WIRE)–ImmunoScape, a biotechnology company focused on next-generation T Cell receptor (TCR)-based immunotherapies, today announced that three abstracts have been accepted for poster presentations at the 2024 American...
ImmunoScape Leadership to Present at Upcoming Industry Conferences CEO Choon-Peng Ng and Vice President of Innovation, Michael Fehlings, Ph.D., will discuss Asia’s role in the “golden age” of biotech and AI in therapeutics SAN DIEGO, Calif., and Singapore – March 1,...
2023 was an exciting year at ImmunoScape, featuring transformative technical progress, new partnerships, expert additions to our leadership team and more. Read our latest newsletter for a look back at the highlights as well as a look ahead at what’s on the way for...
